NCT07490275

Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2026-07-01Est. Completion: 2028-12-31

Enrollment target: 9 participants

Contact

Systemic Lupus ErythematosusAutoimmune Hemolytic Anemia (AIHA)

This is an open lable and single arm study designed to evaluate the safety, PK and PD of Arnovie101 in B cell-mediated A…

Beijing, ChinaEst. completion May 30, 2027

Systemic Lupus ErythematosusInflammatory Myopathy

This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T…

Xuzhou, ChinaCompleted Mar 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.